Medical Device News Magazine

Around 10% of Deaths from Coronary Stenting, Balloon Angioplasty Are Preventable | Complications During Procedures Only Contributed to Death in About 20% of Cases

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally invasive procedure to unclog the arteries that feed the heart.

While PCI, which includes both angioplasty and stenting, is one of the most common operations in the world, it does carry a small (about 1-2%) but significant risk of death. Around 10% of all deaths following percutaneous coronary intervention are potentially preventable, a study led by Michigan Medicine finds.

The results are published in PLOS ONE.

“Deaths in the hospital after PCI are rare and mostly occur in patients who arrive after a heart attack, especially if their cases involve shock,” said senior author Hitinder Gurm, M.B.B.S., chief medical officer at University of Michigan Health and medical director of the Blue Cross Blue Shield of Michigan Cardiovascular Consortium, or BMC2.

“The vast majority of deaths after PCI are unpreventable and related to patients’ underlying conditions for which they are undergoing the procedure. This is a stark change from the 1990s when the majority of deaths were traceable to procedural complications.”

The research team analyzed deaths after PCI occurring at 39 Michigan hospitals participating in BMC2 between 2012 and 2014. These hospitals use procedural and outcome data to inform quality projects to improve care and patient outcomes.

Procedural complications contributed to 20% of the nearly 1,200 deaths reported during the study period. Just over one quarter of the patients who died were considered low risk, meaning a PCI-related mortality risk score estimated they had a 95% or greater chance of survival.

Of the deaths that were considered preventable, 10.1% in total, angioplasty and stenting was deemed to be of low value and potentially avoidable nearly one third of the time.

Researchers say the data suggests a need to focus on optimizing appropriateness of PCI to ensure providers are limiting rare, preventable deaths from this common procedure.

“Our data may help inform how cath labs conduct morbidity and mortality conferences, a common quality improvement practice at many hospitals, by focusing on patients with low predicted risk of mortality who subsequently experienced an adverse event,” said first author Francesco Moroni, M.D., fellow at the Robert M. Berne Cardiovascular Research Center at University of Virginia.

“Such a focus may be an effective method of identifying on periprocedural practices, as opposed to patient-related factors, that may have played a role in a patient’s adverse outcome.”

Additional Authors

Include Milan Seth, M.Sc., of University of Michigan, Francesco Moroni, M.D., of University of Virigina and Università Milano-Bicocca, Hameem U. Changezi, M.D., of McLaren Flint Cardiology, Milind Karve, M.D., of Sparrow Health, Dilip S. Arora, M.D., of Corewell Health South Lakeland, Manoj Sharma, M.D., M.B.A., of Covenant HealthCare, Elizabth Pielsticker, M.D., of Henry Ford-Jackson, Aaron D. Berman, M.D., of Corewell Health William Beaumont University Hospital, Daniel Lee, M.D., of McLaren Bay Heart and Vascular, M. Imran Qureshi, M.D., of DMC Sinai Grace Hospital, and Lorenzo Azzalini, M.D., Ph.D., M.Sc., of Unversity of Washington.

Funding

Support for BMC2 is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program.

Disclosure

Although Blue Cross Blue Shield of Michigan and BMC2 work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

Citation: “Cause and preventability of in-hospital mortality after PCI: a statewide root-cause analysis of 1,163 deaths,” PLOS ONE. DOI: 10.1371/journal.pone.0297596

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”